Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
May 16, 2022
Fred Hutch mourns sudden loss of Dr. Martin ‘Mac’ Cheever
A long career devoted to bringing immunotherapies from bench to bedside
Calling in the backup: expanding DCs to augment vaccine responses
From the Fling and Cheever CITN Central Immune Monitoring Lab, Vaccine and Infectious Disease Division and Clinical Research Division
Dr. Martin 'Mac' Cheever, cancer immunotherapy expert, receives distinguished service award
Honor recognizes his work establishing Cancer Immunotherapy Trials Network
Breaking down HIV exclusions in cancer clinical trials
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life
On immunotherapy trial, long-term survivors of deadly skin cancer point to a hopeful future
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma
Seattle team pivotal to FDA OK on drug for rare skin cancer
UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
Meet Global Oncology's deputy program head
Key early experiences shaped Dr. Thomas Uldrick's path toward HIV-associated cancers, global health
Science to watch in 2018: From immunotherapy to gene therapy, big data to new tech
Fred Hutch experts lend their predictions for the coming year’s advances
Dr. Carl June weaves together HIV and cancer research to advance cures for both
CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference
Immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care
Study found long-lasting responses to immunotherapy drug in patients with Merkel cell carcinoma
Inaugural 'Oncology Summit' addresses academic-industry partnerships
Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care
'Finally showing hope': Immunotherapy trial results transforming care for rare skin cancer
Immunotherapy trial results transforming care for rare skin cancer
6 questions in cancer immunotherapy
From cancer vaccines to engineered T cells, experts weigh in on the big unknowns
Scratching the surface of a rare skin cancer
Immune-boosting therapy shows promise for advanced Merkel cell carcinoma
What Uganda is teaching us about cancer
<p>Fred Hutch-Uganda alliance builds a new cancer center on the shoulders of giants</p>
Cancer Immunotherapy Trials Network selects member sites
Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies
Fred Hutchinson Cancer Research Center to lead immunotherapy clinical trials network
More than two dozen research institutes in the U.S. and Canada to participate
Center awarded $11.5 million for breast cancer research consortium
Porter, Cheever will lead the five-year Seattle-based SPORE in projects including development of targeted treatments for drug-resistant tumors
NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer research consortium
Projects include developing targeted therapies to treat drug-resistant tumors
Immunologists’ ‘team science’ honored
Collaborative achievements in T-cell immunotherapies cited